正在加载公司
Addex Therapeutics Ltd
ADXN · Nasdaq · ·
US$2.81-23.0%9月28日 收盘
- 1M
- -26.8%
- 6M
- -55.7%
- 1Y
- -70.3%
- 5Y
- -98.5%
ADXN · Nasdaq · ·
US$2.81-23.0%9月28日 收盘
截至 2025年6月30日 的季度，与去年同季度相比。
| 指标 | 截至该日的 3 个月2025年6月30日 | 截至该日的 3 个月2023年6月30日 | 变动 |
|---|---|---|---|
| 利润 | -US$2.2M | -US$3.2M | +31.18% |
| 每股收益 | -US$0.02 | -US$0.17 | +85.71% |
| 自由现金流 | -US$2.7M | -US$3.1M | +11.95% |
这些是单季度数字，不是滚动一年——本站其他地方的数字覆盖十二个月，会大得多。季节性业务在两者之间摆动很大：ServiceNow 在十二月季度赚 20 亿美元自由现金流，在六月季度只有 5 亿。
对比对象是去年同一季度，而不是分析师预测。要说“超预期”或“不及预期”需要一致预期数据，那是我们没有的授权数据——而搞错它比不提更糟。
暂无 Addex Therapeutics Ltd 的业绩电话会文字记录。
“The successful raising of USD 2.8 million during the last quarter enables us to continue advancing our in-house GABAB cough program towards clinical development. Coupled with recent regaining of all rights to the GABAB PAM program for substance use disorders from Indivior, due to R&D rationalization following its merger with Supernus Pharmaceuticals, providing a valuable asset for Addex and solidifying our leading portfolio of drug candidates targeting GABAB receptor biology . Our spin-out company, Neurosterix made as well great progress and is on track to complete its Phase 1 clinical study with NTX-253, an M4 positive allosteric modulator with potential in schizophrenia, during the fourth quarter of 2026,”
逐字引自公告，且只在文件将其归于具名人士时才展示。
Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders. Addex’s lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is a Phase 2 ready asset under evaluation for future development in brain injury recovery, including post-stroke and traumatic brain injury recovery. Addex is developing a GABAB PAM drug candidate for substance use disorders that has successfully completed IND enabling studies and a second GABAB PAM program for chronic cough, which is ready to start IND enabling studies. Addex holds a 20% equity interest in a private spin-out company, Neurosterix US Holdings LLC, which is advancing a portfolio of allosteric modulator programs, including M4 PAM for schizophrenia, psychosis and mood-related disorders, and a mGlu7 NAM for mood disorders. In addition, Addex has invested in Stalicla, a private Swiss company pioneering a precision medicine approach for neurodevelopmental and neuropsychiatric disorders. Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares representing its shares are listed on the NASDAQ Capital Market, and trade under the ticker symbol “ ADXN ” on each exchange.
公司自己的描述，取自公告末尾。
引述和公司简介来自 Addex Therapeutics Ltd 于 2026年9月28日 随业绩提交的 6-K 文件；表格根据其季度报告编制。 在 EDGAR 上阅读公告 股价已按拆股和分红复权。